165 related articles for article (PubMed ID: 10658439)
1. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
Bucci M; Iacobitti P; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
[TBL] [Abstract][Full Text] [Related]
2. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
Belcaro G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
[TBL] [Abstract][Full Text] [Related]
3. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
De Sanctis MT; Incandela L; Iacobitti P
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
[TBL] [Abstract][Full Text] [Related]
4. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
Laurora G; Corsi M; Bucci M; Cesarone MR; Belcaro G; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
[TBL] [Abstract][Full Text] [Related]
5. [Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].
Belcaro G; Bucci M; Cesarone MR; Incandela L; De Sanctis MT
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):51-4. PubMed ID: 10658445
[TBL] [Abstract][Full Text] [Related]
6. [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
Laurora G; Belcaro G; Cesarone MR; Incandela L; De Sanctis MT; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):65-8. PubMed ID: 10658448
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
Belcaro G; Cesarone MR; Bucci M; Iacobitti P; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
[TBL] [Abstract][Full Text] [Related]
8. [Circadian variations of cutaneous blood flow in normal subjects and in patients with peripheral arteriopathies. Effect of PGE1 and alpha-cyclodextrin].
Laurora G; Belcaro G
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):45-9. PubMed ID: 10658444
[TBL] [Abstract][Full Text] [Related]
9. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
[TBL] [Abstract][Full Text] [Related]
10. Transcutaneous oxygen pressure as predictive parameter for ulcer healing in endstage vascular patients treated with spinal cord stimulation.
Claeys LG; Horsch S
Int Angiol; 1996 Dec; 15(4):344-9. PubMed ID: 9127776
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Christopoulos D; Agus G; Bavera P; Mondani P; Ippolito E; Flenda F
Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
[TBL] [Abstract][Full Text] [Related]
12. [Intramuscular injections of PGE1 in patients with severe claudication].
Corsi M; Laurora G; Cesarone MR
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):59-63. PubMed ID: 10658447
[TBL] [Abstract][Full Text] [Related]
13. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of cutaneous necrosis risk in peripheral arterial diseases].
D'Eri A; Martini R; Cordova RM; Trevisan G; Andreozzi GM
Minerva Cardioangiol; 2002 Jun; 50(3):239-44. PubMed ID: 12107403
[TBL] [Abstract][Full Text] [Related]
15. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
16. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
[TBL] [Abstract][Full Text] [Related]
17. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
Luzzi R; Belcaro G; Ippolito E; Dugall M; Cesarone MR; Scoccianti M; Errichi BM; Pellegrini L; Ciammaichella G; Ledda A; Ricci A; Cornelli U; Feragalli B; Hosoi M; Corsi M; Simeone E; Agus GB
Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of peripheral arterial occlusive disease with special reference to prostaglandins].
Creutzig A
Z Gesamte Inn Med; 1991 Mar; 46(3):59-67. PubMed ID: 1828125
[TBL] [Abstract][Full Text] [Related]
19. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
[No Abstract] [Full Text] [Related]
20. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
Belcaro G; Laurora G; Nicolaides AN; Agus G; Cesarone MR; DeSanctis MT; Incandela L; Ricci A; Cazaubon M; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Iacobitti P; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Bucci M; Ferrari PG; Corsi M; Pomante P; Mezzanotte L; Geroulakos G
Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
